• Publications
  • Influence
The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients.
The performance of the scale in distinguishing individuals with BP from those with major depressive disorder and the HCL-32 distinguished between BP and MDD with a sensitivity of 80% and a specificity of 51%. Expand
Neural Responses to Sad Facial Expressions in Major Depression Following Cognitive Behavioral Therapy
Data provide further support for elevated amygdala activity in depression and suggest that anterior cingulate activity may be a predictor of treatment response to both pharmacotherapy and CBT. Expand
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for
This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis andExpand
Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial.
People with bipolar disorder and comparatively fewer previous mood episodes may benefit from CBT, and adjunctive CBT was significantly more effective than treatment as usual in people with fewer than 12 previous episodes, but less effective in those with more episodes. Expand
Treatment non‐adherence in affective disorders
The prevalence, predictors and methods for improving medication adherence in unipolar and bipolar affective disorders are reviewed. Expand
Can bipolar disorder be viewed as a multi-system inflammatory disease?
Evidence gathered so far suggests that the multi-system involvement in bipolar disorder is present from the early stages, and therefore requires proactive screening and diagnostic procedures, as well as comprehensive treatment to reduce progression and premature mortality. Expand
Nonadherence with mood stabilizers: prevalence and predictors.
Backward stepwise logistic regression demonstrated that partially adherent subjects were best distinguished from adherent subjects by a more frequent past history of nonadherence, denial of severity of illness, and greater duration of being prescribed a mood stabilizer. Expand
Rumination-focused cognitive behaviour therapy for residual depression: a case series.
Preliminary evidence that rumination-focused CBT may be an efficacious treatment for medication--refractory residual depression is provided, with generalised improvement in depression and co-morbidity. Expand
Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial.
Adding rumination-focused CBT to TAU significantly improved residual symptoms and remission rates and is the first randomised controlled trial providing evidence of benefits ofRumination- focused CBT in persistent depression. Expand